Clinical significance of the humoral immune response to modified LDL.
about
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on PhysiopathologySimvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering EffectModel IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoproteinThe association between serum levels of oxLDL-lgG and oxLDL-lgM autoantibody with adult acute myeloblastic leukaemiaUnique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery diseaseDiabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature.Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations.An immunohistochemical analysis to validate the rationale behind the enhanced immunogenicity of D-ribosylated low density lipo-protein.Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.Oxidatively modified low density lipoprotein (LDL) inhibits TLR2 and TLR4 cytokine responses in human monocytes but not in macrophages.Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.Serum fructosamine, serum glycated albumin and serum glycated β-lipoprotein in type 2 diabetes mellitus patients with and without microvascular complicationsCan we vaccinate against atherosclerosis?Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk.Fcγ receptor deficiency attenuates diabetic nephropathy.The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.Serum lipids modify periodontal infection - C-reactive protein association.Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.A role for autoantibodies in atherogenesis.
P2860
Q26744760-A03F30E6-E385-4692-9CD1-A09F65E0ED87Q28553042-DBA257A2-A3AA-4ACE-9A01-6280DC4A9774Q31055400-674406AE-07BA-440D-868F-D782E9B3CA3CQ33711818-FF0290EF-2BA5-4A46-903A-B6B00C9C5AD7Q34166358-D5D763F7-411C-4604-A618-1528DB501821Q34350546-A5F061D0-7C52-4B26-B156-6C63BE24A510Q34434803-CFEBB819-6B98-4D9D-86E6-8F80F51FF9F0Q34506699-A183B9DC-3BA6-4389-B8A2-C65A96B0E7F6Q34542912-46F4F634-2F29-48C2-98D3-09E676CF2E62Q35212898-3232538D-32CA-43AD-B349-23D96CE63021Q35789087-84A2AE34-DBAD-46E3-A323-96A85BCBFC0EQ35976427-7B57E68C-4935-4B43-BBC0-074D7CA1C14EQ36020265-A17C5139-2254-402C-94D1-78079FB7C3A9Q36078752-4F495A72-B0A6-4A64-AF6D-D601453945F4Q36723319-A5A642F5-DD30-4F6C-BD23-8588F6AF9C7EQ37426374-90578C1A-FB6B-4467-8E60-F5DC23102209Q38137846-54361E1D-C129-4DA8-9984-2981D1BD2186Q38494149-20DBD572-25FE-49D1-8926-1A66F259E317Q41951561-0E719B8C-1456-4AE3-86F6-CC1BDF2A83C1Q42201820-0D7EECD9-260D-4DA5-8B0F-1040671AD123Q43738638-005EAD4E-CD0F-4BEB-BE73-D4ED1E4B4E1AQ46380048-C305A10C-4D0E-421C-A237-D7AFC1E9DAA0Q47623831-A2E792D0-145C-4A63-9B53-E908096F968E
P2860
Clinical significance of the humoral immune response to modified LDL.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical significance of the humoral immune response to modified LDL.
@ast
Clinical significance of the humoral immune response to modified LDL.
@en
type
label
Clinical significance of the humoral immune response to modified LDL.
@ast
Clinical significance of the humoral immune response to modified LDL.
@en
prefLabel
Clinical significance of the humoral immune response to modified LDL.
@ast
Clinical significance of the humoral immune response to modified LDL.
@en
P2860
P1433
P1476
Clinical significance of the humoral immune response to modified LDL.
@en
P2093
Gabriel Virella
Maria F Lopes-Virella
P2860
P356
10.1016/J.CLIM.2009.04.001
P577
2009-05-08T00:00:00Z